> top > docs > PMC:7306567 > spans > 33009-38353 > annotations

PMC:7306567 / 33009-38353 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
340 2832-2853 Disease denotes Stepstone Pharma GmbH
341 5281-5299 Disease denotes FL van de Veerdonk MESH:C536528

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T164 106-109 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T165 291-294 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T166 355-358 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T167 395-398 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T168 422-425 Disease denotes BMS http://purl.obolibrary.org/obo/MONDO_0006687
T169 460-463 Disease denotes BMS http://purl.obolibrary.org/obo/MONDO_0006687
T170 473-476 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T171 500-502 Disease denotes he http://purl.obolibrary.org/obo/MONDO_0017319
T172 532-535 Disease denotes BMS http://purl.obolibrary.org/obo/MONDO_0006687
T173 545-548 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T174 997-1000 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T175 1313-1316 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T176 1462-1465 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T177 1495-1498 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T178 1638-1641 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T179 2594-2597 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T180 2886-2889 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T181 3060-3063 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T182 3134-3137 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T183 3168-3171 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T184 3286-3289 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T185 3507-3510 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T186 3569-3572 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T187 3694-3697 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T188 4750-4753 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T189 4962-4965 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T190 5201-5204 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088
T191 5248-5251 Disease denotes MSD http://purl.obolibrary.org/obo/MONDO_0010088

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T218 310-313 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T219 597-598 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T220 715-718 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T221 945-948 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T222 1120-1123 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T223 1808-1811 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T224 2258-2261 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T225 2432-2434 http://www.ebi.ac.uk/efo/EFO_0000265 denotes Da
T226 2945-2947 http://purl.obolibrary.org/obo/CLO_0001980 denotes BJ
T227 2957-2960 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T228 2966-2967 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T229 3361-3364 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T230 3406-3409 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T231 3473-3476 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T232 3524-3527 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T233 3649-3652 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T234 3731-3732 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T235 4063-4065 http://purl.obolibrary.org/obo/CLO_0007706 denotes MH
T236 4073-4076 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T237 4511-4514 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T238 4687-4690 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T239 4758-4761 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T240 4883-4886 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T241 4998-5001 http://purl.obolibrary.org/obo/CLO_0051582 denotes has
T242 5130-5131 http://purl.obolibrary.org/obo/CLO_0001020 denotes a
T243 5281-5283 http://purl.obolibrary.org/obo/CLO_0003358 denotes FL
T244 5300-5303 http://purl.obolibrary.org/obo/CLO_0051582 denotes has

LitCovid-PD-CHEBI

Id Subject Object Predicate Lexical cue chebi_id
T233 57-59 Chemical denotes PE http://purl.obolibrary.org/obo/CHEBI_16038|http://purl.obolibrary.org/obo/CHEBI_17553|http://purl.obolibrary.org/obo/CHEBI_74762
T236 1666-1668 Chemical denotes GE http://purl.obolibrary.org/obo/CHEBI_73801
T237 2144-2146 Chemical denotes OA http://purl.obolibrary.org/obo/CHEBI_138856
T238 2796-2798 Chemical denotes DR http://purl.obolibrary.org/obo/CHEBI_73445
T239 4063-4065 Chemical denotes MH http://purl.obolibrary.org/obo/CHEBI_74703
T240 4304-4306 Chemical denotes TF http://purl.obolibrary.org/obo/CHEBI_74862
T241 4501-4503 Chemical denotes TR http://purl.obolibrary.org/obo/CHEBI_74825
T242 5281-5283 Chemical denotes FL http://purl.obolibrary.org/obo/CHEBI_91150

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T244 0-33 Sentence denotes Compliance with ethical standards
T245 35-56 Sentence denotes Conflicts of interest
T246 57-199 Sentence denotes PE Verweij reported grants from Gilead Sciences, MSD, Pfizer and F2G, and non-financial support from OLM and IMMY, outside the submitted work.
T247 200-571 Sentence denotes BJA Rijnders was the investigator for studies supported by Gilead Sciences, Janssen-Cilag, MSD, Pfizer, ViiV; has received research grants from Gilead and MSD; was an invited speaker for Gilead, MSD, Pfizer, Jansen-Cilag, BMS; and an advisory board member for BMS, Abbvie, MSD, Gilead, Jansen-Cilag; he received travel support from BMS, Abbvie, MSD, Gilead, Jansen-Cilag.
T248 572-849 Sentence denotes RJM Brüggemann served as a consultant to Astellas Pharma, Inc., F2G, Amplyx, Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc., and has received unrestricted and research grants from Astellas Pharma, Inc., Gilead Sciences, Merck Sharp & Dohme Corp., and Pfizer, Inc.
T249 850-934 Sentence denotes All contracts were through Radboudumc, and all payments were invoiced by Radboudumc.
T250 935-1021 Sentence denotes E Azoulay has received fees for lectures from Pfizer, Gilead, MSD, Alexion and Baxter.
T251 1022-1108 Sentence denotes His institution received research support from Fisher&Payckle, Jazz pharma and Gilead.
T252 1109-1412 Sentence denotes M Bassetti has received funding for scientific advisory boards, travel and speaker honoraria from Angelini, Astellas, AstraZeneca, Basilea, Bayer, BioMèrieux, Cidara, Correvio, Cubist, Menarini, Molteni, MSD, Nabriva, Paratek, Pfizer, Roche, Shionogi, Tetraphase, Thermo Fisher and The Medicine Company.
T253 1413-1559 Sentence denotes S Blot received research funding from Pfizer and MSD, travel support from Pfizer, MSD and Gilead, and is an invited speaker for Pfizer and Gilead.
T254 1560-1763 Sentence denotes T Calandra reported advisory board membership from Astellas, Basilea, Cidara, MSD, Sobi, ThermoFisher and GE Healthcare and data monitoring board membership from Novartis, all outside the submitted work.
T255 1764-1797 Sentence denotes Fees are paid to its institution.
T256 1798-2143 Sentence denotes CJ Clancy has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this project, served on advisory boards or consulted for Astellas, Merck, the Medicines Company, Cidara, Scynexis, Shionogi, Qpex and Needham & Company, and spoken at symposia sponsored by Merck and T2Biosystems.
T257 2144-2705 Sentence denotes OA Cornely is supported by the German Federal Ministry of Research and Education and the European Commission, and has received research grants from, is an advisor to, or received lecture honoraria from Actelion, Allecra Therapeutics, Amplyx, Astellas, Basilea, Biosys UK Limited, Cidara, Da Volterra, Entasis, F2G, Gilead, Grupo Biotoscana, Janssen Pharmaceuticals, Matinas, Medicines Company, MedPace, Melinta Therapeutics, Menarini Ricerche, Merck/MSD, Octapharma, Paratek Pharmaceuticals, Pfizer, PSI, Rempex, Scynexis, Seres Therapeutics, Tetraphase, Vical.
T258 2706-2750 Sentence denotes T Chiller reported no conflicts of interest.
T259 2751-2795 Sentence denotes P Depuydt reported no conflicts of interest.
T260 2796-2897 Sentence denotes DR Giacobbe reported honoraria from Stepstone Pharma GmbH and an unconditional grant from MSD Italia.
T261 2898-2944 Sentence denotes NAF Janssen reported no conflicts of interest.
T262 2945-3019 Sentence denotes BJ Kullberg has been a scientific advisor for Amplyx, Cidara and Scynexis.
T263 3020-3187 Sentence denotes K Lagrou received consultancy fees from MSD, SMB Laboratoires Brussels and Gilead, travel support from Pfizer and MSD and speaker fees from Gilead, MSD, FUJIFILM WAKO.
T264 3188-3351 Sentence denotes C Lass-Florl received research funding from Pfizer, Gilead and Egger, travel support from Pfizer, MSD, and Gilead, and is an invited speaker for Pfizer and Gilead.
T265 3352-3458 Sentence denotes RE Lewis has received research support from Merck and has served as an invited speaker for Gilead, Cidara.
T266 3459-3635 Sentence denotes P Wei-Lun Liu has received research grants from MSD, Pfizer, and has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is an advisor to Pfizer, Gilead.
T267 3636-3773 Sentence denotes O Lortholary has served as an invited speaker for Gilead, MSD, Pfizer, Astellas Pharma, and is a consultant for Gilead, Novartis and F2G.
T268 3774-4010 Sentence denotes J Maertens reported personal fees and non-financial support from Basilea Pharmaceuticals, Bio-Rad Laboratories, Cidara, F2G Ltd., Gilead Sciences, Merck, Astellas, Scynexis, and Pfizer Inc. and grants from Gilead Sciences, IMMY and OLM.
T269 4011-4062 Sentence denotes I Martin-Loeches reported no conflicts of interest.
T270 4063-4303 Sentence denotes MH Nguyen has been awarded investigator-initiated research grants from Astellas, Merck, Melinta and Cidara for projects unrelated to this study and served on advisory boards for Astellas, Merck, the Medicines Company, Scynexis and Shionogi.
T271 4304-4500 Sentence denotes TF Patterson reported grants from Cidara to UT Health San Antonio; personal fees from Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga, Toyama and United Medical outside the submitted work.
T272 4501-4674 Sentence denotes TR Rogers has received grants from Gilead Sciences, lecture honoraria from Gilead Sciences and Pfizer Healthcare Ireland, and advisory board membership with Menarini Pharma.
T273 4675-4788 Sentence denotes JA Schouten has received unrestricted educational and research grants from MSD and has been an advisor to Pfizer.
T274 4789-4873 Sentence denotes All contracts were through Radboudumc, and all payments were invoiced by Radboudumc.
T275 4874-4993 Sentence denotes I Spriet has received unrestricted research grants, speaker fees and travel grants from MSD, Pfizer, Gilead and Cidara.
T276 4994-5042 Sentence denotes She has served in the advisory board for Cidara.
T277 5043-5152 Sentence denotes L Vanderbeke is supported by the Flanders Research Foundation (FWO Vlaanderen) through a doctoral fellowship.
T278 5153-5280 Sentence denotes J Wauters reported grants from Gilead Sciences, MSD and Pfizer, and non-financial support from MSD, outside the submitted work.
T279 5281-5344 Sentence denotes FL van de Veerdonk has served as an invited speaker for Gilead.